A federal review board voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is non-binding. The FDA has given no indication on whether it will follow the advice. The move came after weeks of stakeholder sessions. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have no real proof of safety or help for most uses. The call could reshape how the agency handles a part of the wellness market that is surging ahead. Industry players are waiting to see if the agency adopts the plan. A spokesperson offered no clear schedule for a reaction. Supporters argue the change would expand access to compounds people say help them. Health groups warn that looser rules could allow poor oversight across a wide-open market. The panel vote only sets up a possible shift, and the ultimate call rests with the regulator.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch